"Exhaled Breath Condensate" in Allogeneic Stem Cell Recipients and the Value in Follow-up

Gazi University

Status: Unknown

Conditions: Exhaled Breath Condensate

Treatments: Other: Exhaled breath condensate

Study type: Observational

Funder types: Other

Identifiers

NCT02318316

EBC01

Details and patient eligibility

About

The most effective treatment of hematologic malignancies and some benign hematological diseases is allogeneic stem cell transplantation therapy. Pulmonary complications can occur after allogeneic stem cell transplantation. And these complications effect mortality and morbidity in these patients. In this study we want to investigate the use of exhaled breath condensate (EBC) collection which is a simple and completely noninvasive method. By this way we hope to detect pulmonary complications early. EBC, has been implicated in the pathophysiology of inflammatory airway diseases such as cystic fibrosis, asthma, chronic obstructive pulmonary disease (COPD) and bronchiectasis. EBC, has not been investigated before in patients who underwent stem cell transplantation.

Enrollment: 80 estimated patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• hematologic malignancies or benign hematological diseases that allogeneic stem cell transplantation performed

Exclusion criteria

• allogeneic stem cell transplantation patients with Asthma or COPD

Trial design

80 participants in 1 patient group

EBC level

Description:

Exhaled breath condensate level of allogeneic stem cell transplantation patients

Treatment:

Other: Exhaled breath condensate